Approximately 1 in 10 people experience migraine headaches, and a new study points to hope for these people who suffer from this sometimes debilitating condition.

These severe headaches can last for hours or more and may be accompanied by light or sound sensitivity as well as nausea. 

In a recent study published in the New England Journal of Medicine, investigators looking at the effect of the monoclonal antibody fremanezumab, randomized over 1,000 migraine sufferers into one of three groups that received either an injection of fremanezumab (675 mg the first month and then a placebo at weeks four and eight); monthly treatments of fremanezumab with a starting dose of 675 mg and then 225 mg for the second and third month; or a placebo for all three months. 

More than 43 percent of volunteers taking the lowest dose of the drug fremanezumab and 50 percent of volunteers taking the highest dose experienced approximately half as many migraine headaches.

Side effects from the medication were relatively mild.